⌘K
t
| Date | 13 Oct 2022 |
| Time | 14:55:30 |
| Category | AGMs and other meetings |
| ID | 8407C |
Feedback plc
Result of AGM & Proposed Share Consolidation
Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, announces that at the Annual General Meeting ("AGM") held today all resolutions were duly passed.
The results of the poll (including proxy votes on the resolutions) are included below.
|
Resolutions |
Votes For** |
% of votes cast*** |
Votes Against |
% of votes cast*** |
Votes Withheld*** |
Total votes cast*** |
|
1) To receive and adopt the Company's annual accounts for the year ended 31 May 2022 together with the Directors' report and the Auditors' report thereon |
1,435,070,825 |
100.00 |
0 |
0.00 |
1,636,537 |
1,435,070,825 |
|
2) To receive and approve the report on Directors' remuneration for the year ended 31 May 2022 |
666,547,017 |
57.85 |
485,714,290 |
42.15 |
83,017,483 |
1,152,261,307 |
|
3) To re-appoint Price Bailey LLP as Auditor of the Company |
1,300,785,111 |
100.00 |
0 |
0.00 |
1,636,537 |
1,300,785,111 |
|
4) To authorise the Directors to determine the fees payable to the Auditor |
1,435,070,825 |
100.00 |
0 |
0.00 |
1,636,537 |
1,435,070,825 |
|
5) To elect Anesh Patel as a Director of the Company |
1,435,037,825 |
100.00 |
33,000 |
0.00 |
1,636,537 |
1,435,070,825 |
|
6) To elect Annemijn Eschauzier as a Director of the Company |
1,435,037,825 |
100.00 |
33,000 |
0.00 |
1,636,537 |
1,435,070,825 |
|
7) To re-elect Rory Shaw as a Director of the Company |
949,356,535 |
100.00 |
0 |
0.00 |
487,350,827 |
949,356,535 |
|
Special Business |
||||||
|
8) That the Directors be and are hereby generally and unconditionally authorised to allot relevant securities pursuant to section 551 of the Companies Act 2006 |
1,388,179,455 |
96.73 |
46,891,370 |
3.27 |
1,636,537 |
1,435,070,825 |
|
Special Resolution 9) To resolve that the Directors be empowered to allot equity securities for cash and/or to sell equity securities held as treasury shares for cash
|
1,388,596,455 |
96.76 |
46,474,370 |
3.24 |
1,636,537 |
1,435,070,825 |
|
10) That every 200 ordinary shares of £0.0025 each in the capital of the Company are hereby consolidated into one ordinary share of £0.50 |
1,376,208,959 |
95.90 |
58,861,866 |
4.10 |
1,636,537 |
1,435,070,825 |
|
Special resolution 11) That, the Articles be amended by the insertion of a new article 2.5 |
1,376,208,959 |
95.90 |
58,861,866 |
4.10 |
1,636,537 |
1,435,070,825
|
|
|
|
|
|
|
|
|
Notes:
* "Votes For" include votes giving the Chairman discretion.
** Percentages exclude "Votes Withheld".
*** "Votes Withheld" are not votes in law and do not count in the number of votes counted for or against a resolution.
**** "Total votes cast" do not include withheld votes.
Share Consolidation
Following the approval of the Consolidation Resolution (resolution 10 above), every 200 ordinary shares of £0.0025 each (the "Existing Shares") that are in issue as at 6.00 p.m. today will be consolidated into one new ordinary share of £0.50 each (the "New Ordinary Shares"). Other than the change in nominal value, the New Ordinary Shares arising on implementation of the Share Consolidation will have the same rights as the Existing Ordinary Shares, including voting and other rights.
The New Ordinary Shares arising from the Share Consolidation will be admitted to trading on AIM from 8.00 a.m. on 14 October 2022 ("Admission") with ISIN number GB00BJN59X09 and SEDOL code BJN59X0.
Total Voting Rights
Following Admission, the Company's issued share capital will comprise 13,334,659 New Ordinary Shares with voting rights. This figure of 13,334,659 New Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the Disclosure Rules and Transparency Rules of the United Kingdom Financial Conduct Authority.
Save as defined herein, capitalised terms have the same meaning as in the Company's notice of AGM which is available on the Company's website.
-Ends-
Enquiries:
|
Feedback plc Tom Oakley, CEO Anesh Patel, CFO |
+44 (0) 20 3997 7634 |
|
|
|
|
Panmure Gordon (UK) Limited (NOMAD and Broker) Emma Earl/Freddy Crossley (Corporate Finance) Rupert Dearden (Corporate Broking) |
+44 (0)20 7886 2500 |
|
|
|
|
Walbrook PR Ltd; |
Tel: 020 7933 8780 or feedbackplc@walbrookpr.com |
|
Paul McManus/Nick Rome |
07980 541 893 or 07748 325 236 or 07884 664 686 |
About Feedback
Feedback plc helps clinical teams to make better decisions faster for patients. We design products that enhance clinician access to patient data and to their colleagues. Our unique approach centres around individual patient episodes, into which we pull relevant clinical data from hospital systems and around which we build remote clinical teams for collaboration. As a result, we produce a digital infrastructure that makes patient data available to clinicians in multiple settings, in a format that enables them to meaningfully interact with it, providing flexibility to clinicians and free movement of patients between provider settings - clinicians can practice from anywhere and patients can attend any care provider for treatment.
Our products Bleepa and CareLocker work together to deliver unparalleled value to our customers. Bleepa is our application layer and sits on top of CareLocker as our data layer. Bleepa is a clinician facing platform that displays clinical results from a patient's CareLocker at a certified and regulated quality, that is suitable for clinical use and enables dialogue on a patient-by-patient basis with colleagues through a secure, auditable chat interface that links back to the patient medical record. The CareLocker data storage model is built around the patient. Our vision is one where relevant clinical data is always available to the patient as well as to any care setting that they may attend - a federated data architecture with the patient as the tenant.
The Company has a number of growth opportunities domestically and internationally across a range of markets including the NHS, the veterinary market and private healthcare providers and its highly scalable Software as a Service ("SaaS")-based revenue model is expected to provide increasing levels of visibility as the Company grows its customer base.